In a phase 3 trial, Axpaxli, a tyrosine kinase inhibitor, achieved its superiority primary endpoint vs. aflibercept for the ...

Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.

From bionic eyes to cell and gene therapies in clinical therapies, it's an exciting time for emerging technologies aiming to ...

In a statement, EyePoint CEO Jay Duker, M.D., lauded Campbell’s “proven track record of successfully launching innovative ...

The evolution of computing has significantly impacted both business and personal lives, expanding from personal computers to ...

Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release outlining the positive topline results from our SOL-1 Phase III clinical trial of AXPAXLI, ...

PT compared system responsiveness and on-device AI performance on AMD Ryzen CPU-powered Dell Pro 14, HP ProBook 4 G1a ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...

Ocular Therapeutix Inc. (NASDAQ:OCUL) shares dropped 35% on Tuesday even after the company announced favorable results from ...

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...

AMD adds Day 0 support for Alibaba Qwen 3.5 on Instinct MI300X, MI325X, and MI355X with ROCm, enabling 256K context and multimodal AI.